The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

The last decade has witnessed great advances in our understanding of the genetic and
biological basis of childhood acute lymphoblastic leukemia (ALL), the development of …

Acute lymphoblastic leukemia (ALL) is the most successful paradigm of how risk-adapted
therapy and detailed understanding of the genetic alterations driving leukemogenesis and …

B-acute lymphoblastic leukemia (B-ALL) comprises a wide variety of subtypes with diverse
clinical and biological features and outcomes. Risk-stratified and targeted therapy according …

Human B-lymphopoiesis is a dynamic life-long process that starts in utero by around six post-
conception weeks. A detailed understanding of human fetal B-lymphopoiesis and how it …

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic
alterations with high heterogeneity. Precise subtypes with distinct genomic and/or gene …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a
main cause of death in children despite recent improvements in cure rates. In the past …

Aneuploidy, the gain or loss of chromosomes in a cell, is a hallmark of cancer. Although our
understanding of the contribution of aneuploidy to cancer initiation and progression is …

CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute
lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) …

Aberrant DNA methylation constitutes a key feature of pediatric acute lymphoblastic
leukemia at diagnosis, however its role as a predisposing or early contributor to leukemia …